The European Medicines Agency (EMA) recommended granting a conditional marketing authorisation for the Covid-19 jab for adults.
The Medicine and Healthcare products Regulatory Agency (MHRA) are still conducting a review on the vaccine.
Emer Cooke, executive director of EMA said: “This vaccine provides us with another tool to overcome the current emergency.
“It is a testament to the efforts and commitment of all involved that we have this second positive vaccine recommendation just short of a year since the pandemic was declared by WHO (World Health Organisation).
“As for all medicines, we will closely monitor data on the safety and effectiveness of the vaccine to ensure ongoing protection of the EU public.
“Our work will always be guided by the scientific evidence and our commitment to safeguard the health of EU citizens.”
The decision comes just days after the end of the Brexit transition period.
Coronavirus: Celebrities who have been vaccinated
As part of the transition period, until the end of December 2020, Covid-19 vaccine candidates authorised via the EMA would automatically be valid in the UK.
It is the second jab recommended by the EMA after the Pfizer/BioNTech vaccine.
The Moderna vaccine was hailed as “tremendously exciting” when the US pharmaceutical company posted its phase three clinical trial results in November.
Its trial involved more than 30,000 people, half of whom received the vaccine and the other half received a placebo.
The jab demonstrated a 94.1 per cent efficacy in the trial and showed 90.9 per cent efficacy in participants at risk of severe Covid-19.
Regulators in the US have already approved the jab and it is being rolled out in the States.
Officials in the UK have pre-ordered seven million Moderna jabs, enough to vaccinate 3.5 million people with two doses each.
But the Government has said that the jabs won’t be available in Britain until “spring at the earliest”, should it be approved for use.
Additional reporting by PA Media.
